IMZ Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$897K Buy
748
+1
+0.1% +$1.02K 0.28% 20
2026
Q1
$687K Buy
747
+7
+0.9% +$7.1K 0.26% 21
2025
Q4
$796K Buy
740
+1
+0.1% +$956 0.29% 20
2025
Q3
$564K Buy
739
+86
+13% +$64K 0.21% 24
2025
Q2
$504K Buy
653
+1
+0.2% +$777 0.2% 24
2025
Q1
$538K Sell
652
-10
-2% -$8.32K 0.24% 22
2024
Q4
$511K Buy
662
+13
+2% +$10.8K 0.23% 22
2024
Q3
$576K Hold
649
0.27% 23
2024
Q2
$587K Buy
649
+1
+0.2% +$800 0.29% 22
2024
Q1
$504K Buy
648
+2
+0.3% +$1.42K 0.26% 23
2023
Q4
$506K Buy
+646
New +$377K 0.27% 24

Other funds holding LLY

IMZ Advisory's LLY Position: Q2 2026 in Review

IMZ Advisory increased its Eli Lilly (LLY) stake by 0.13% in Q2 2026, buying an estimated $1.02K and bringing the position to 748 shares worth $897K. The position accounts for 0.28% of the portfolio, ranked #20.

IMZ Advisory first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • IMZ Advisory held 748 shares of Eli Lilly worth $897K as of Q2 2026.
  • IMZ Advisory bought 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
  • Eli Lilly made up 0.28% of IMZ Advisory's portfolio in Q2 2026, its #20 holding.
  • IMZ Advisory first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on IMZ Advisory's 13F filing for Q2 2026, filed 7 Jul 2026.